Tolerability of Rofecoxib versus Naproxen

Jeffrey R. Lisse; Monica Perlman; Adam B. Polis; Gregory P. Geba

doi:10.7326/0003-4819-140-12-200406150-00023

Letters |15 June 2004

Tolerability of Rofecoxib versus Naproxen

Jeffrey R. Lisse, MD; Monica Perlman, MD, MPH; Adam B. Polis, MA; Gregory P. Geba, MD, MPH

Article, Author, and Disclosure Information

IN RESPONSE:

It is important to understand differences between dual cyclooxygenase-inhibiting NSAIDs and coxibs for effective use in appropriate populations. The ADVANTAGE (Assessment of Differences between Vioxx And Naproxen To Ascertain Gastrointestinal tolerability and Effectiveness) study was the largest trial to enroll patients with osteoarthritis using less restrictive entry criteria. In addition, it permitted use of low-dose aspirin during the trial and involved a sample that was characteristic of patients seen in clinical practice with typical comorbid conditions. Treatment of osteoarthritis with rofecoxib and naproxen in this setting was designed to study “real-world” conditions. Other important coxib studies, such as the VIGOR study, which included patients with rheumatoid arthritis who were not taking low-dose aspirin, and CLASS (Celecoxib Long-term Arthritis Safety Study), which included both patients with osteoarthritis and those with rheumatoid arthritis and permitted low-dose aspirin, had differences in design (1, 2).

FULL TEXT

PDF

Not Available

2004 American College of Physicians

Letters |15 June 2004

Tolerability of Rofecoxib versus Naproxen

See Also

Content

Information For

Services

Awards

Other Resources

Follow Annals On

Letters |15 June 2004

Tolerability of Rofecoxib versus Naproxen

See Also

Content

Information For

Services

Awards

Other Resources

Follow Annals On

You need a subscription to this content to use this feature.